ArticleNature communications2021

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.

Michael Maschan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.